Literature DB >> 2235801

Do non-steroidal anti-inflammatory drugs or smoking predispose to Helicobacter pylori infection?

D G Maxton1, E D Srivastava, P J Whorwell, D M Jones.   

Abstract

Susceptibility to Helicobacter pylori infection is a poorly understood phenomenon. This study was undertaken to establish whether either smoking or chronic non-steroidal anti-inflammatory drug (NSAID) consumption might in some way predispose to H. pylori infection and hence lead to peptic ulceration. Serological evidence of H. pylori infection was assessed in 100 consecutive subjects receiving NSAIDs without any evidence of gastrointestinal upset and 100 matched controls. All subjects had a full assessment of their smoking habits. Sixty-three per cent of patients taking NSAIDs compared to 51% of controls had evidence of H. pylori infection (NS). Smoking habit also had no effect on H. pylori colonization. The ulcerogenic potential of NSAIDs and smoking does not appear to be mediated via a prediposition to H. pylori infection.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2235801      PMCID: PMC2426894          DOI: 10.1136/pgmj.66.779.717

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  15 in total

1.  Increased gastric secretory capacity in smokers without gastrointestinal lesions.

Authors:  S Massarrat; F Enschai; P M Pittner
Journal:  Gut       Date:  1986-04       Impact factor: 23.059

2.  Campylobacter pyloridis--a new factor in peptic ulcer disease?

Authors:  B J Rathbone; J I Wyatt; R V Heatley
Journal:  Gut       Date:  1986-06       Impact factor: 23.059

Review 3.  Campylobacter pyloridis, gastritis, and peptic ulceration.

Authors:  C S Goodwin; J A Armstrong; B J Marshall
Journal:  J Clin Pathol       Date:  1986-04       Impact factor: 3.411

Review 4.  Campylobacter pyloridis gastritis: the past, the present, and speculations about the future.

Authors:  D Y Graham; P D Klein
Journal:  Am J Gastroenterol       Date:  1987-04       Impact factor: 10.864

5.  Antibody to the gastric campylobacter-like organism ("Campylobacter pyloridis")--clinical correlations and distribution in the normal population.

Authors:  D M Jones; J Eldridge; A J Fox; P Sethi; P J Whorwell
Journal:  J Med Microbiol       Date:  1986-08       Impact factor: 2.472

6.  Cigarette smoking reduces human gastric luminal prostaglandin E2.

Authors:  D R McCready; L Clark; M M Cohen
Journal:  Gut       Date:  1985-11       Impact factor: 23.059

7.  The effects of ibuprofen, indomethacin, aspirin, naproxen, and placebo on the gastric mucosa of normal volunteers: a gastroscopic and photographic study.

Authors:  F L Lanza; G L Royer; R S Nelson; T T Chen; C E Seckman; M F Rack
Journal:  Dig Dis Sci       Date:  1979-11       Impact factor: 3.199

8.  Pyloric Campylobacter infection and gastroduodenal disease.

Authors:  B J Marshall; D B McGechie; P A Rogers; R J Glancy
Journal:  Med J Aust       Date:  1985-04-15       Impact factor: 7.738

9.  Outpatient endoscopic survey of smoking and peptic ulcer.

Authors:  C C Ainley; I C Forgacs; P W Keeling; R P Thompson
Journal:  Gut       Date:  1986-06       Impact factor: 23.059

Review 10.  Non-steroidal anti-inflammatory drugs and the gastric mucosa: mechanisms of damage and protection.

Authors:  C J Hawkey
Journal:  Aliment Pharmacol Ther       Date:  1988       Impact factor: 8.171

View more
  2 in total

Review 1.  Optimizing acid suppression for treatment of acid-related diseases.

Authors:  R H Hunt; C Cederberg; J Dent; F Halter; C Howden; I N Marks; S Rune; R P Walt
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

2.  Lifestyle and anti-Helicobacter pylori immunoglobulin G antibody among outpatients.

Authors:  N Hamajima; M Inoue; K Tajima; S Tominaga; A Matsuura; S Kobayashi; Y Ariyoshi
Journal:  Jpn J Cancer Res       Date:  1997-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.